Candel Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shareholders voted for company leadership and chose who watches the company's money.
Defines what the chief money officer earns and receives if laid off without cause.
Management updates investors on strategy and progress at a public event.
Shows how much money the company made or lost in the first quarter.
Shows how much money the company made or lost in the first quarter.
Annual report details all company finances, risks and operations for the entire year.
Shows how much money the company made or lost for the entire year.
Stocky reads Candel Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Candel Therapeutics, Inc.'s most recent tracked filing was a 8-K on 24 Jun 2026: Four directors elected; KPMG ratified as auditor.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.